Inovio Pharmaceuticals clinical trials
Also known as Genetronics.
The registry lists 35 studies whose lead sponsor is Inovio Pharmaceuticals or the company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 35studies on the registry
- 0open to participants now
What it is testing
The drugs Inovio Pharmaceuticals’ studies test, most studies first; none is open now — 7 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 35 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 08
- 09
- 10
- 411
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 6 started before 2008. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Inovio Pharmaceuticals.
- Inovio Pharmaceuticals31 studiesSame company
Something wrong?
- VGX Pharmaceuticals, LLC4 studies →Acquired — became part of Inovio Pharmaceuticals, Jun 1, 2009 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 35 of 35.
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)Active, not recruitingNCT03491683Phase 1/2
- INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial CarcinomaCompletedNCT03502785Phase 1/2
- INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)CompletedNCT04398433Phase 1/2
- Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy VolunteersCompletedNCT04588428Phase 2
- REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)CompletedNCT03721978Phase 3
- Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 ExposureTerminatedNCT04642638Phase 2/3
- Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)CompletedNCT03180684Phase 2
- REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)CompletedNCT03185013Phase 3
- VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2CompletedNCT03499795Phase 2
- Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in GhanaCompletedNCT04093076Phase 1
- Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy VolunteersWithdrawnNCT05430958Phase 1
- Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy VolunteersCompletedNCT04336410Phase 1
- Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell CarcinomaTerminatedNCT00198315Phase 3
- Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell CarcinomaTerminatedNCT00198328Phase 3
- A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical CancerCompletedNCT02172911Phase 1/2
- Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell CarcinomaCompletedNCT02163057Phase 1/2
- Safety, Tolerability and Immunogenicity of INO-4500 in Healthy VolunteersCompletedNCT03805984Phase 1
- Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B SubjectsCompletedNCT02431312Phase 1
- Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy VolunteersCompletedNCT02464670Phase 1
- hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of RelapseCompletedNCT02960594Phase 1
- Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and MalignanciesCompletedNCT02241369Phase 1
- A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3CompletedNCT01304524Phase 2
- Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100CompletedNCT01188850Phase 1
- Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate CancerCompletedNCT02514213Phase 1
- Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous CancerCompletedNCT00198276Phase 4
- Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck CancerCompletedNCT00198263Phase 4
- Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy AdultsCompletedNCT01142362Phase 1
- Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3CompletedNCT00685412Phase 1
- A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001CompletedNCT01403155Phase 1
- A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza VirusCompletedNCT01405885Phase 1
- Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult ParticipantsCompletedNCT01082692Phase 1
- Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected SubjectsCompletedNCT00352911Phase 2
Sponsor listed in the registry: VGX Pharmaceuticals, LLC · First submitted before VGX Pharmaceuticals, LLC became part of Inovio Pharmaceuticals
- Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected PatientsCompletedNCT00255177Phase 2
Sponsor listed in the registry: VGX Pharmaceuticals, LLC · First submitted before VGX Pharmaceuticals, LLC became part of Inovio Pharmaceuticals
- Multiple-Dose Study of VGX-1027 in Healthy SubjectsCompletedNCT00760396Phase 1
Sponsor listed in the registry: VGX Pharmaceuticals, LLC · First submitted before VGX Pharmaceuticals, LLC became part of Inovio Pharmaceuticals
- Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy SubjectsCompletedNCT00627120Phase 1
Sponsor listed in the registry: VGX Pharmaceuticals, LLC · First submitted before VGX Pharmaceuticals, LLC became part of Inovio Pharmaceuticals